For generations, medicine has struggled to extend its certainties to those who need them most — the very old. A decade-long Australian trial involving nearly 10,000 adults over 70 has now answered one of clinical medicine's most persistent silences: statins, long proven to protect younger hearts, reduce the risk of first heart attack or stroke by 30% in older populations as well. The finding arrives as the world ages rapidly and cardiovascular disease moves toward epidemic scale, offering both a medical clarification and a quiet reminder that the most vulnerable are too often the least studied
Landmark trial shows statins cut heart attack, stroke risk 30% in adults over 70
An estimated 21,000 older Australians experience major cardiovascular events annually, with risk increasing significantly after age 70.
A safe, effective measure for lowering that risk will be a huge reassurance.
Mark
So this trial followed nearly 10,000 people over a decade. That's a serious commitment. What made researchers decide now was the time to test statins in people over 70?
Mimi
For a long time, older people were largely absent from the big statin trials. Doctors knew the drugs worked in younger populations, but they didn't have solid evidence for someone in their seventies or eighties. That gap created real uncertainty in clinical practice.
Luke
But I want to be careful here—were older people excluded from earlier trials, or did they just enroll fewer of them? There's a difference between deliberate exclusion and natural variation in who volunteers.
Mimi
Fair point. The source says older people were "historically overlooked," which suggests it was more about who got enrolled than an explicit ban. The STAREE trial was designed specifically to answer the question for this age group.
Mark
And the result was a 30 percent reduction in first cardiovascular events. That's substantial. Does that mean one in three heart attacks or strokes was prevented?
Mimi
Not quite. It means the risk was 30 percent lower in the statin group compared to the placebo group. So if the baseline risk was, say, 10 events per 100 people over the decade, the statin group might see 7. The absolute benefit depends on individual risk.
Luke
Right, and the source doesn't give us the actual event rates, so we can't calculate the number needed to treat—how many people you'd need to give statins to prevent one event. That's important information for a patient deciding whether to start.
Mark
The trial involved over 3,400 GPs across Australia. Does that mean the results are specific to Australia, or do they apply more broadly?
Mimi
The community-based design in Australia is actually a strength for generalizability. These weren't specialized research clinics; they were ordinary GP practices. So the results should apply to similar healthcare settings elsewhere, though different populations might have different baseline risks.
Luke
That said, the source doesn't tell us the demographic breakdown of the participants. Were they mostly white? What was their socioeconomic status? Those details matter for understanding who the findings apply to.
Mark
The researchers mentioned updated treatment guidelines coming next. How quickly does that usually happen?
Mimi
Guidelines typically take time—medical organizations need to review the evidence, convene committees, reach consensus. But with a study this large and in a major journal, change usually follows within a year or two.
Luke
And we should note: this is one trial, however rigorous. Guidelines will likely incorporate this alongside other evidence. It's not the final word, just a very important new piece.
O Pulso
- An estimated 21,000 older Australians suffer major cardiovascular events each year, yet until now no large-scale trial had confirmed whether statins — medicine's most prescribed preventive tool — actually worked for them.
- The absence of evidence created a clinical limbo, leaving doctors uncertain and older patients either over-treated by habit or under-treated by caution.
- The STAREE trial — 10 years, nearly 10,000 participants, 3,400 community GPs — delivered a 30% reduction in first cardiovascular events, a result robust enough to shift the conversation from doubt to action.
- Researchers and cardiologists are now calling on the medical community to update clinical guidelines and on older patients to initiate conversations with their GPs before the next preventable event occurs.
- With global cardiovascular disease projected to double by 2050, the trial's community-based design means its findings apply not to rare research subjects but to the ordinary patients sitting in waiting rooms right now.
For generations, medicine has struggled to extend its certainties to those who need them most — the very old. A decade-long Australian trial involving nearly 10,000 adults over 70 has now answered one of clinical medicine's most persistent silences: statins, long proven to protect younger hearts, reduce the risk of first heart attack or stroke by 30% in older populations as well. The finding arrives as the world ages rapidly and cardiovascular disease moves toward epidemic scale, offering both a medical clarification and a quiet reminder that the most vulnerable are too often the least studied.
For decades, statins reliably protected younger patients from heart attack and stroke — but the elderly were rarely included in the trials that established that trust. Clinicians were left in an uncomfortable position: prescribe a drug with uncertain evidence, or withhold a potentially life-saving therapy from their most vulnerable patients. A landmark study released this week closes that gap.
The STAREE trial, led by researchers at Monash University, followed nearly 10,000 independently living adults over 70 for a full decade. Half received a statin; half received a placebo. The outcome was unambiguous — those on statins saw a 30% reduction in first major cardiovascular events. Published in the New England Journal of Medicine and presented at the European Society of Cardiology Congress 2026, it stands as the first large-scale randomized controlled trial to address this age group directly.
What distinguishes the study is not only its size but its setting. More than 3,400 general practitioners across Australia enrolled and managed patients in ordinary community practices — not specialized research centers. Lead researcher Adjunct Professor Sophia Zoungas called the results a turning point, one that should prompt updated clinical guidelines and give both patients and families genuine reassurance that a safe, effective option exists.
The urgency is real. Cardiovascular disease currently affects around 600 million people worldwide, a figure expected to surpass one billion by 2050. Age alone elevates risk, and older adults have historically been the least represented in the trials meant to protect them. Co-author and GP Mark Nelson urged older patients to raise statin therapy with their doctors, while the National Heart Foundation noted that this evidence reframes prevention — showing that beginning treatment late in life can still meaningfully alter its course.
Australia now positions itself as a leader in healthy aging research at a moment when global populations are aging faster than ever. The immediate challenge is translation: turning a landmark finding into updated guidelines, and updated guidelines into conversations that might quietly redirect the health trajectories of millions.
For decades, doctors have prescribed statins to people with high cholesterol, watching the drugs reliably lower the odds of heart attack and stroke. But one question lingered unanswered: did they actually work for people over 70? The oldest patients were rarely included in the trials that proved statins' worth in younger populations, leaving clinicians uncertain whether to recommend them to their most vulnerable patients. A landmark study released this week provides the first rigorous answer.
Researchers at Monash University conducted a randomized controlled trial called STAREE—Statins in Reducing Events in the Elderly—that followed nearly 10,000 independently living adults older than 70 for a decade. Half received a statin; half received a placebo. The result was clear: those taking statins experienced a 30 percent reduction in the risk of a first major cardiovascular event, whether heart attack or stroke. The findings, published in the New England Journal of Medicine and presented at the European Society of Cardiology Congress 2026, represent the first large-scale evidence that the drugs work in this age group.
The trial's scale and design set it apart. More than 3,400 general practitioners across Australia enrolled patients and managed their care in real-world community settings, not in specialized research centers. This breadth matters because it shows the results apply to the ordinary patients doctors see every day, not just carefully selected research subjects. Adjunct Professor Sophia Zoungas, the lead researcher, framed the finding as a turning point. She said the evidence should prompt updated clinical guidelines that help doctors decide when to prescribe statins to older patients, and she emphasized that knowing a safe, effective option exists offers reassurance to both patients and their families.
The timing of this research reflects a growing urgency. Cardiovascular disease affects roughly 600 million people globally today; that number is projected to exceed one billion by 2050. In Australia alone, approximately 21,000 older adults suffer major cardiovascular events each year. Age itself is a risk factor—people over 70 face elevated danger regardless of lifestyle or other circumstances. The disease burden falls heaviest on those least studied in clinical trials, a gap the STAREE trial was designed to close.
Mark Nelson, a general practitioner and co-author of the study, stressed that the trial's community-based design makes the findings immediately actionable. He urged older patients to discuss statin therapy with their GPs, framing it as one tool among many for maintaining cardiovascular health. Derek Chew, chief scientific and medical officer at the National Heart Foundation of Australia, which helped fund the work, noted that while statins have prevented cardiovascular events for decades, this study demonstrates they can do so even when treatment begins late in life—a shift in understanding that could reshape how doctors approach prevention in their oldest patients.
The research positions Australia as a leader in healthy aging research at a moment when the world's population is aging faster than ever before. Zoungas described STAREE as a benchmark for international trials that can inform preventive care globally. The next step is implementation: whether the medical community will translate these findings into updated guidelines and whether older patients will have the conversations with their doctors that might change the trajectory of their health.
Citações Notáveis
This was a particularly important trial because it was conducted in the community, with more than 3,400 GPs taking part across Australia.— Professor Mark Nelson, co-author and general practitioner
Knowing there is a safe and effective measure for lowering that risk will be a huge reassurance to older people and their families.— Professor Sophia Zoungas, lead researcher
Quer a matéria completa?
Leia o original em Medical Xpress ↗
Politics & Governance